A Study for Subjects Who Are Participating in an Astellas-sponsored ASP8273 Study

Stopped Following recommendation by SOLAR Study IDMC, Astellas closed enrollment in ASP8273 studies.

Conditions

• Subjects With NSCLC With an EGFR Activating Mutation

Interventions

• DRUG: ASP8273

Sponsor

Astellas Pharma Global Development, Inc.